西格列汀联合预混胰岛素治疗脆性糖尿病伴高脂血症疗效和安全性的回顾性研究
投稿时间:2017-12-19  修订日期:2018-03-05  点此下载全文
引用本文:薛梅萍,郑茹萍,林惠娥,甘惠贞.西格列汀联合预混胰岛素治疗脆性糖尿病伴高脂血症疗效和安全性的回顾性研究[J].药学实践杂志,2018,36(5):468~470
摘要点击次数: 32
全文下载次数: 39
作者单位E-mail
薛梅萍 解放军180医院药学科, 福建 泉州 362000  
郑茹萍 解放军180医院药学科, 福建 泉州 362000  
林惠娥 解放军180医院药学科, 福建 泉州 362000  
甘惠贞 解放军180医院药学科, 福建 泉州 362000 13599220436@139.com 
中文摘要:目的 探讨西格列汀联合预混胰岛素治疗脆性糖尿病伴高脂血症的疗效和安全性。方法 采用回顾性分析法,收集解放军180医院内分泌科门诊脆性糖尿病伴高脂血症患者158例,其中,单用预混胰岛素治疗的78例为对照组,西格列汀联合预混胰岛素治疗的80例为治疗组,随访时间为36周。比较两组治疗前后糖化血红蛋白(HbAlc)、空腹血糖(FPG)、餐后血糖(PPG)、空腹C肽、餐后2 h C肽,每日血糖谷峰浓度均差(△TP)、血脂水平变化及低血糖发生率。结果 治疗后联合组FPG、PPG、△TP、总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白(LDL-C)较治疗前均有明显下降(P<0.05,P<0.01),且均低于对照组(P<0.05,P<0.01);联合组空腹C肽和餐后2 h C肽较治疗前显著升高(P<0.01),且均高于对照组(P<0.05)。结论 西格列汀联合预混胰岛素治疗脆性糖尿病伴高脂血症可显著改善患者血糖和血脂水平,且不良反应更少。
中文关键词:脆性糖尿病  西格列汀  预混胰岛素  疗效  安全性
 
Retrospective study on efficacy and safety of combination therapy of sitagliptin and premixed insulin in the treatment of brittle diabetes with hyperlipidemia
Abstract:Objective To investigate the efficacy and safety of combination therapy with sitagliptin and premixed insulin in the treatment of brittle diabetes with hyperlipidemia. Methods 158 patients treated at endocrinology clinic in our hospital for brittle diabetes with hyperlipidemia were selected for the retrospective analysis. 78 patients received insulin alone were severed as the control group while 80 patients treated with sitagliptin and premixed insulin as the treatment group. The follow-up time was 36 weeks. The levels of HbAlc, FPG, PPG, fasting C peptide, postprandial 2 h C peptide, average difference of daily trough and peak blood glucose level (△TP), blood lipid level and hypoglycemia incidences were compared before and after treatment between two groups. Results After treatment,the levels of FPG, PPG, △TP, TC, TG and LDL-C in the combination therapy group were significantly lower than the level before treatment (P<0.05,P<0.01). Those values in the treated group were also lower than the control group (P<0.05,P<0.01). The fasting C peptide and postprandial 2 h C peptide in the combination therapy group were significantly higher than level before treatment (P<0.01).Those values were higher in the treated group compared to the control group (P<0.05). Conclusion Combination therapy of sitagliptin and premixed insulin for the treatment of brittle diabetes with hyperlipidemia can significantly improve patients' blood glucose and lipid levels with less adverse reactions.
keywords:brittle diabetes  sitagliptin  premixed insulin  efficacy  safety
查看全文  查看/发表评论  下载PDF阅读器
关闭

分享按钮